123.65 (C-5'), 120.93 (C-5,3a) , 117.77 (C-3a'), 115.82 (C-7'), 109.24 (C-7), 107.26 (C-3);
CI-MS m/z 341, 343 (M+H)
+
6-Bromoindirubin (3)
1 H NMR (DMSO, 400 MHz, δ ppm, J in Hz) 11.10 (1H, s, N'-H), 11.00 (1H, s, N-H), 8.67 (1H, d, J = 8.1 Hz, H-4), 7.65 (1H, d, J = 7.5 Hz, H-4'), 7.58 (1H, t, J = 7.5 Hz, H-6'), 7.42 (1H, d, J = 7.5 Hz, H-7'), 7.22 (1H, dd, J = 8.1, 1.7 Hz , H-5), 7.04 (1H, d, J = 1.7 Hz, H-7), 7.03 (1H, t, J = 7.5 Hz, H-5').
13 C NMR (DMSO, 200 MHz, δ ppm) 188.85 (C-3'), 170.98 (C-2), 152.58 (C-7a'), 142.59 (C-7a), 138.86 (C-2'), 137.31 (C-6'), 125.99 (C-4), 124.52 (C-4'),
123.78 (C-5), 121.58 (C-3,5'), 120.86 (C-3a), 119.06 (C-3a'), 113.64 (C-7'), 112.39 (C-7), NaF, 1 mM phenylphosphate, 10 µg leupeptin/ml, 10 µg aprotinin/ml, 10 µg soybean trypsin inhibitor/ml and 100 µM benzamidine. Buffer A -10 mM MgCl 2 , 1 mM EGTA, 1 mM DTT, 25 mM Tris-HCl pH 7.5, 50 µg heparin/ml. Buffer C -homogenization buffer but 5 mM EGTA, no NaF and no protease inhibitors.
Kinase preparations and assays
Kinase activities were assayed in Buffer A or C (unless otherwise stated), at 30°C, at a final ATP concentration of 15 µM. Blank values were subtracted and activities calculated as pmoles of phosphate incorporated during a 10 min. incubation. The activities are usually expressed in % of the maximal activity, i.e. in the absence of inhibitors. Controls were performed with appropriate dilutions of dimethylsulfoxide. In a few cases phosphorylation of the substrate was assessed by autoradiography after SDS-PAGE.
GSK-3α/β was purified from porcine brain by affinity chromatography on immobilized axin [S1] . It was assayed, following a 1/100 dilution in 1 mg BSA/ml 10 mM DTT, with 5 µl 40 µM GS-1 peptide, a specific GSK-3 substrate, (YRRAAVPPSPSLSRHSSPHQSpEDEEE, synthesized by the Peptide Synthesis Unit, Institute of Biomolecular Sciences, University of Southampton, U.K.), in buffer A, in the presence of 15 µM [γ-32 P] ATP (3,000 Ci/mmol; 1 mCi/ml) in a final volume of 30 µl. After 30 min. incubation at 30°C, 25 µl aliquots of supernatant were spotted onto 2.5 x 3 cm pieces of Whatman P81 phosphocellulose paper, and, 20 sec. later, the filters were washed five times (for at least 5 min. each time) in a Tyrian purple -derived indirubins inhibit GSK-3 solution of 10 ml phosphoric acid/liter of water. The wet filters were counted in the presence of 1 ml ACS (Amersham) scintillation fluid. CDK1/cyclin B was extracted in homogenisation buffer from M phase starfish (Marthasterias glacialis) oocytes and purified by affinity chromatography on p9 CKShs1 -sepharose beads, from which it was eluted by free p9 CKShs1 as previously described [S2] . The kinase activity was assayed in buffer C, with 1 mg histone H1 /ml, in the presence of 15 µM [γ-32 P] ATP (3,000
Ci/mmol; 1 mCi/ml) in a final volume of 30 µl. After 10 min. incubation at 30°C, 25 µl aliquots of supernatant were treated as described above. CDK5/p25 was reconstituted by mixing equal amounts of recombinant mammalian CDK5 and p25 expressed in E. coli as GST (Glutathione-S-transferase) fusion proteins and purified by affinity chromatography on glutathione-agarose (vectors kindly provided by Dr. J.H. Wang) (p25 is a truncated version of p35, the 35 kDa CDK5 activator). Its activity was assayed in buffer C as described for CDK1/cyclin B.
Other kinases were expressed, purified and assayed as described previously [S3] .
Affinity chromatography on immobilized indirubin

Immobilization of indirubin on a matrix
Indirubin was synthesized by the condensation of 3-acetoxyindol with isatin (all chemicals were from Aldrich) under basic conditions. The indirubin affinity resin compound was then prepared by the formation of an oxime between indirubin and NH 2 -O-(PEG) 3 -N 3 with pyridine at 110˚C. The azide group was further reduced to amine, and the resulting compound was captured by active ester agarose (Affi-Gel 15, BioRad). The completion of the resin capture was monitored by the disappearance of the peak of the indirubin derivative in LC/MS. 
Crystallization of kinases with indirubins
GSK-3β
Human GSK-3β was cloned, and expressed, in the Bac-to-Bac baculovirus expression system (Life Technologies), as previously described [38] . Frozen cells from a 5 liter culture were lyzed by thawing, and hand homogenizing on ice in buffer A (50 mM HEPES-NaOH pH 7.5, 300 mM NaCl, 50 mM NaF, 1 mM Na orthovanadate, supplemented with protease inhibitors).
The cell extract was centrifuged (48,000 g for 60 min at 4 o C) and the clarified supernatant was mixed with 10 ml Talon metal affinity resin (Clontech) for 2 hr at 4 o C. The resin was pelleted by centrifugation at 700 g for 3 min at 4 o C, packed into an XK 16/20 column (Amersham Biosciences), washed with 20 column volumes of buffer A, and 20 column volumes of buffer A + 5 mM imidazole. The protein was eluted with 50 mM HEPES-NaOH pH 7.0, 300 mM NaCl, 200 mM imidazole, 50 mM NaF, 1 mM Na orthovanadate. 2 mM EDTA and 2 mM DTT were added to the eluted protein, which was then incubated overnight at 4 o C with approximately 3 mg (or 20,000 units) of rTEV protease, to remove the histidine tag. The protein was concentrated to 15 ml using Vivaspin 20 ml centrifugal concentrator (Vivascience), and desalted (HiPrep 26/10 desalting column, Amersham Biosciences) in 50 mM Hepes-NaOH pH 7.0, 300 mM NaCl. The protein was mixed with 10 ml Talon for 2 hr at contaminants. 1 mM EDTA and 1 mM DTT were added to the protein, which was concentrated and diluted in ion exchange buffer A (25 mM HEPES-NaOH pH 7.0, 1 mM DTT) to obtain a NaCl concentration of 50 mM. The protein was applied to an 8 ml Source 15S column, HR 10/10 (Amersham Biosciences). The resin was washed with buffer A and the protein was eluted with a 0-500 mM NaCl gradient over 50 column volumes, in 25 mM HEPES-NaOH pH7.0, 1 mM DTT. The protein was concentrated to ~ 10 mg/ml using a 2ml centricon centrifugal concentrator (Amicon), and the purified GSK-3β was stored at -80 o C.
Samples of unphosphorylated and tyrosine phosphorylated GSK-3β (130 µM Table S1 . Data processing was carried out using MOSFLM and SCALA [S4] . The structure was solved by molecular replacement methods [S5] using the GSK-3β structure as search model. Refinement was carried out in CNS [S6] using torsion angle molecular dynamics. A model for the bromoindirubin was built and refinement parameters generated from the HIC-UP server [S7] . In the final stages of refinement 125 water molecules were added.
CDK5/p25
A dominant-negative version of the CDK5 kinase containing a point mutation of Asp144 to asparagine was used in the co-crystallization experiments as this mutation substantially improved the expression yields [40] . The CDK5/p25 complex was expressed, purified and crystallized as described previously [40] . After CDK5/p25 crystals had formed, small amounts of indirubin-3'-oxime powder were added to the crystallization drops using a cat's whisker, and soaking was protracted for 2 h at 20°C. During this time, binding of the inhibitor to the crystals could be detected by the coloring of the crystals, which assumed a bright purple Tyrian purple -derived indirubins inhibit GSK-3 color. The crystals were dialyzed overnight in cryo-buffer (mother liquor containing 20% glycerol) as described [40] and flash-frozen. Data were collected from a single crystal at beamline ID14-1 at ESRF, using a wavelength of 0.93 Å, as summarized in Table S1 . Data processing was carried out using programs DENZO and SCALEPACK [S8] . Table S1 . Table S1 . Structure determination of the GSK-3β -BIO and CDK5/p25-IO complexes.
Statistics of the dataset used and of the refined structure. *** R free is equivalent to R cryst but is calculated using a disjoint set of reflections excluded from refinement.
GSK-3β -BIO
